Live moderated video webcast discussion of AC5 Advanced Wound System among management and Key Opinion Leaders on Wednesday, October 28th at 12:00 PM ET FRAMINGHAM, Mass., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB:ARTH) (“Arch” or the “Company”), developer of novel liquid, gel and solid hemostatic and wound… Read More..
- Nearly half of all patients in Phase 3 trial continue to see sustained and statistically significant improvement in their response rates when treated with SGX301 through 18 weeks (Cycle 3), reinforcing positive SGX301 primary endpoint treatment response - SGX301 remains safe and well tolerated with no systemic exposure through… Read More..
Growth now expected to exceed 500% from fiscal Q4 2020 to fiscal Q1 2021 KELOWNA, BC / ACCESSWIRE / October 22, 2020 / Lexaria Bioscience Corp. (OTCQX:LXRP)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in oral drug delivery platforms, is pleased to announce that it is exceeding expectations for volume of servings of… Read More..